Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasurgratinib in advanced solid tumors with FGFR alterations
NCT04962867Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tasurgratinib in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jun 2021; status: recruiting.
02
Drugs
tasurgratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04962867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962867.